Discordance of HER2-Low between Primary Tumors and Matched Distant Metastases in Breast Cancer.
HER2 dynamics
HER2 overexpression
HER2-low
HER2-zero
antibody-drug conjugate
de-novo metastasis
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
23 Feb 2023
23 Feb 2023
Historique:
received:
02
02
2023
revised:
19
02
2023
accepted:
21
02
2023
entrez:
11
3
2023
pubmed:
12
3
2023
medline:
12
3
2023
Statut:
epublish
Résumé
We examined differences in HER2 expression between primary tumors and distant metastases, particularly within the HER2-negative primary breast cancer cohort (HER2-low and HER2-zero). The retrospective study included 191 consecutive paired samples of primary breast cancer and distant metastases diagnosed between 1995 and 2019. HER2-negative samples were divided into HER2-zero (immunohistochemistry [IHC] score 0) and HER2-low (IHC score 1+ or 2+/in situ hybridization [ISH]-negative). The main objective was to analyze the discordance rate between matched primary and metastatic samples, focusing on the site of distant metastasis, molecular subtype, and de novo metastatic breast cancer. The relationship was determined by cross-tabulation and calculation of Cohen's Kappa coefficient. The final study cohort included 148 paired samples. The largest proportion in the HER2-negative cohort was HER2-low [primary tumor 61.4% (
Identifiants
pubmed: 36900203
pii: cancers15051413
doi: 10.3390/cancers15051413
pmc: PMC10000561
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Lancet Oncol. 2016 Mar;17(3):367-377
pubmed: 26874901
Front Oncol. 2022 Jan 17;11:774577
pubmed: 35111669
Ann Oncol. 2013 Dec;24(12):2990-4
pubmed: 24013581
Front Oncol. 2022 Jun 16;12:906011
pubmed: 35785207
Semin Cancer Biol. 2021 Jul;72:123-135
pubmed: 32112814
BMC Med. 2022 Mar 17;20(1):105
pubmed: 35296300
Eur J Cancer. 2022 Mar;163:35-43
pubmed: 35032815
Lancet Oncol. 2021 Oct;22(10):e427
pubmed: 34592188
Clin Breast Cancer. 2022 Jun;22(4):391-397
pubmed: 35337735
Breast Cancer Res Treat. 2017 Jan;161(2):259-267
pubmed: 27885439
Eur J Cancer. 2017 Sep;83:116-124
pubmed: 28735068
J BUON. 2019 Jan-Feb;24(1):20-25
pubmed: 30941947
Oncogene. 2009 Feb 12;28(6):803-14
pubmed: 19060928
Lancet Oncol. 2021 Aug;22(8):1151-1161
pubmed: 34252375
Science. 1987 Jan 9;235(4785):177-82
pubmed: 3798106
Breast. 2021 Dec;60:62-69
pubmed: 34481367
Breast Cancer Res Treat. 2019 Jun;175(2):401-408
pubmed: 30806922
Cancer Diagn Progn. 2022 May 3;2(3):316-323
pubmed: 35530657
Lancet Oncol. 2021 Aug;22(8):1139-1150
pubmed: 34339645
Pathobiology. 2022;89(5):278-296
pubmed: 35500561
Eur J Cancer. 2022 Sep;173:10-19
pubmed: 35839597
JAMA Oncol. 2022 Apr 01;8(4):1-4
pubmed: 35113160
J Clin Oncol. 2020 Apr 20;38(12):1346-1366
pubmed: 31928404
Int J Cancer. 2023 Apr 1;152(7):1476-1489
pubmed: 36408915
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
J Natl Cancer Inst. 2018 Jun 1;110(6):568-580
pubmed: 29315431
Cancers (Basel). 2021 Dec 01;13(23):
pubmed: 34885167
Breast Cancer Res. 2022 Mar 21;24(1):22
pubmed: 35307014
J Clin Oncol. 2018 Jul 10;36(20):2105-2122
pubmed: 29846122
Mod Pathol. 2020 Dec;33(12):2499-2506
pubmed: 32620918
Clin Cancer Res. 2009 Dec 1;15(23):7381-8
pubmed: 19920100
Pathologie (Heidelb). 2022 Nov;43(6):457-466
pubmed: 36227345
Science. 1989 May 12;244(4905):707-12
pubmed: 2470152
N Engl J Med. 2022 Mar 24;386(12):1143-1154
pubmed: 35320644
Sci Rep. 2022 Jul 28;12(1):12974
pubmed: 35902644
J Clin Oncol. 2022 Sep 10;40(26):3088-3090
pubmed: 35926153
JAMA Oncol. 2022 Sep 15;:
pubmed: 36107417
ESMO Open. 2023 Feb;8(1):100747
pubmed: 36563519
Cancers (Basel). 2021 Jun 05;13(11):
pubmed: 34198891
Breast Cancer. 2022 Sep;29(5):844-853
pubmed: 35729304
J Clin Oncol. 2020 Feb 10;38(5):444-453
pubmed: 31821109
J Clin Oncol. 2004 Aug 15;22(16):3302-8
pubmed: 15310773
NPJ Breast Cancer. 2021 Jan 4;7(1):1
pubmed: 33397968
Am J Transl Res. 2019 Sep 15;11(9):6110-6116
pubmed: 31632579
N Engl J Med. 2017 Jul 13;377(2):122-131
pubmed: 28581356
Lancet Oncol. 2016 Jun;17(6):791-800
pubmed: 27179402
Ann Surg Oncol. 2022 Dec;29(13):8026-8034
pubmed: 35933542
N Engl J Med. 2019 Feb 14;380(7):617-628
pubmed: 30516102
N Engl J Med. 2012 Jan 12;366(2):109-19
pubmed: 22149875
Eur J Cancer. 2014 Jan;50(2):277-89
pubmed: 24269135
Oncol Rep. 2015 Jul;34(1):504-10
pubmed: 25976081
N Engl J Med. 2022 Jul 7;387(1):9-20
pubmed: 35665782
N Engl J Med. 2006 Dec 28;355(26):2733-43
pubmed: 17192538
Endocrinology. 2003 Mar;144(3):1032-44
pubmed: 12586780
Cancers (Basel). 2022 Aug 31;14(17):
pubmed: 36077795
Eur J Cancer. 2022 Oct;174:277-286
pubmed: 36116830
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
NPJ Breast Cancer. 2022 May 20;8(1):66
pubmed: 35595761
NPJ Breast Cancer. 2021 Oct 12;7(1):137
pubmed: 34642348
N Engl J Med. 2020 Feb 13;382(7):597-609
pubmed: 31825569
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153
Breast Cancer. 2022 Mar;29(2):234-241
pubmed: 34622383
JAMA Netw Open. 2022 Sep 1;5(9):e2231170
pubmed: 36107428
Radiat Res. 2009 Jan;171(1):9-21
pubmed: 19138055
N Engl J Med. 2008 Mar 27;358(13):1409-11
pubmed: 18367751
J Clin Oncol. 2010 Oct 1;28(28):4307-15
pubmed: 20697084
Nature. 2009 Oct 8;461(7265):809-13
pubmed: 19812674